In separate filings with the exchanges, the companies announced a licensing and supply agreement to co-market the injection, aimed at expanding access to advanced therapies for diabetes and weight management.
The partnership will cover semaglutide injection (15 mg/3 ml) delivered through a patient-friendly reusable pen device, they said.
Under the agreement, Lupin will have semi-exclusive rights to co-market the drug in India under the brands Semanext and Livarise, while Zydus will continue to market it under Semaglyn, Mashema and Alterme.
Also read: Andhra Petro suspends Vizag plant operations as HPCL halts propylene supply
Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, “Keeping patients’ needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life.”
About the partnership, he said, “We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India.”
As part of the deal, Lupin will pay Zydus upfront licensing fees and milestone-based payments linked to predefined targets.
Nilesh Gupta, Managing Director, Lupin, said the collaboration is a “significant step” in strengthening their commitment to provide advanced treatment options for cardio-metabolic diseases.
“As GLP-1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on
addressing unmet patient needs,” he added.
The companies said the collaboration combines Zydus’ product development capabilities with Lupin’s extensive domestic distribution network, with the aim of improving access to next-generation therapies for cardio-metabolic conditions.
Semaglutide, a GLP-1 receptor agonist, is used for the treatment of type 2 diabetes and is also prescribed for chronic weight management, alongside diet and exercise, particularly in patients with obesity or related comorbidities.
Both companies said the agreement will help strengthen their presence in India’s growing market for advanced diabetes and obesity treatments, while supporting healthcare professionals with broader access to innovative treatment options.
Shares of Lupin were trading 2,296.90, while those of Zydus Life were trading 0.63% up at ₹892.45 as of 12.48 pm. In the last six months, Lupin has delivered about 13% returns, while Zydus Life shares have declined over 13%.
